Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study

Publication | Open Access

DOI Full Paper Access

Citations

References

2006

Year

Pascal Piedbois, D. Serin, Franck Priou, P. Laplaige, S. Greget, Élisabeth Angellier, É. Teissier, Jean François Berdah, Michel Fabbro, B. Valenza,

Annals of Oncology

Node-positive Breast CancerBreast OncologyReverse SequenceMedicinePharmacologyClinical TrialsBreast CancerPharmacotherapyCancer TreatmentOncologyDose-dense Adjuvant Chemotherapy